Investor Profile: SemperVirens — Thesis, Cheque Size & How to Apply

SemperVirens Venture Capital is a San Francisco venture fund founded in 2018, and SemperVirens funding is built around one practical insight: selling into employers, health plans and financial institutions is a distribution problem, not just a product problem. The firm invests in companies driving workforce transformation, and then opens its network of employers, brokers, insurers and hospital systems to help them sell. For a founder in health, wealth or work, that distribution edge is the point of the pitch.

Investment thesis

SemperVirens backs startups building AI for the world's most complex markets, specifically companies shaping the future of health, wealth and work. Its companies typically sell to and through employers, which means buyers are committees, compliance teams and benefits leaders rather than individual consumers. The firm's homepage reports more than $200 million in directly influenced annual recurring revenue and more than 5,500 customer introductions for its portfolio.

Sectors and stages

The firm is an early-stage investor across workforce technology, healthcare technology and financial technology, including enterprise, healthcare and financial-services innovation. Its accelerator is designed for startups from pre-seed through Series A, especially those planning to sell into employers, brokers, payers, carriers, human-capital platforms or health systems. Consumer-only products without an employer or institutional channel are a weaker fit.

Fund size and cheque size

SemperVirens reported about $300 million in assets under management and a portfolio of more than 70 companies in its June 2025 accelerator announcement. A standard cheque size is not publicly disclosed on the pages read for this profile, so none is stated here. Founders should discuss cheque size and stage fit directly with the team, and weigh the distribution support alongside the cash.

Notable portfolio

Companies featured in the firm's own testimonials include Stepful, whose chief executive credits SemperVirens' structured approach to workforce retention strategy, Midi Health, whose co-founder says the firm has been a partner since its pre-seed round, and Multimodal, whose chief executive cites introductions that opened transformative partnerships. Those three examples show the pattern: health and workforce companies that need enterprise buyers, not just users.

Partners and team

Co-founder and Managing Partner Robby Peters leads the firm's public work on the accelerator, and the firm reports more than 200 executive advisors and dozens of large-scale distribution partners. Its advisor groups include senior leaders from major employers, health plans and insurers, which is precisely the network a founder needs when the buyer is an enterprise benefits team rather than a single champion.

Programmes, credits and perks

The firm's real programme is the SemperVirens Accelerator, launched in June 2025. It runs in quarterly cycles, is primarily virtual, and offers product-market-fit insights through Innovation Councils, distribution and go-to-market support through curated introductions and briefings, and scaling help through a Trusted Partner Suite of vetted vendors, tools and advisors. Its first cohort included Clasp, Sunny Health AI, Outro and Onboarded. No separate credits or perks bundle was found.

How to apply for funding

Startups interested in the accelerator can apply at sempervirensvc.com/accelerator, the route named in the firm's own announcement. For a direct investment conversation, use the contact route on sempervirensvc.com, and lead with the buyer: which employers, payers or health systems will buy, who decides, and what distribution help you need most. A pitch that ignores the buyer will miss what this firm is for.